EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection
The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen
The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...
FiercePharma2h
EMA about-faces, backs Eisai and Biogen's Leqembi in restricted Alzheimer's population
Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...
MedPage Today on MSN1d
Alzheimer's Researcher Placed on Leave; War on Drug Recovery; Lax Coroner Oversight
Science also found that a planned clinical trial for a stroke drug candidate that Zlokovic helped develop ... and as ...
STAT18h
Mild Alzheimer’s patients won’t save Cassava Sciences
As we count down toward the December readout of Cassava Sciences’ simufilam Phase 3 clinical trial in Alzheimer’s disease, it ...
Alzheimer’s caregivers need updated drug rules to give families more time and peace | Opinion
Alzheimer’s disease robs patients of so much more than their health. It can rewire their personalities and undermine a ...
New Atlas4d
Alzheimer’s drug trial raises concerns for accelerating cognitive decline
While growing evidence suggests that there’s a link between blood iron levels and the development of Alzheimer’s disease, new ...
STAT1h
Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved
Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...
ALZFORUM1h
Tau Modification Drugs Take a Hit with Negative Trial
Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...
Is Ozempic the modern wonder drug? All the conditions the weight loss jab can tackle — from addiction to Alzheimer’s
"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...
BioSpace3d
Leqembi, Kisunla and Beyond: The Next Wave of Alzheimer’s at CTAD 2024
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...